Filing Details

Accession Number:
0001140361-17-018662
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-05-05 18:13:43
Reporting Period:
2017-05-03
Filing Date:
2017-05-05
Accepted Time:
2017-05-05 18:13:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1588972 Recro Pharma Inc. REPH () CA
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1440771 Stonepine Capital Management, Llc 919 Nw Bond Street
Suite 204
Bend OR 97703
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2017-05-03 13,808 $7.79 2,860,509 No 4 S Indirect See Notes
Common Stock Disposition 2017-05-03 2,340 $7.79 2,858,169 No 4 S Indirect See Notes
Common Stock Disposition 2017-05-04 172,000 $7.69 2,686,169 No 4 S Indirect See Notes
Common Stock Disposition 2017-05-04 29,160 $7.69 2,657,009 No 4 S Indirect See Notes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Notes
No 4 S Indirect See Notes
No 4 S Indirect See Notes
No 4 S Indirect See Notes
Footnotes
  1. This is a weighted average price. These securities were sold in multiple transactions at prices ranging from $7.7768 to $7.977. The Filers undertake to provide to the Issuer, any security holder of the issuer or the SEC staff, on request, information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 6 of this Form 4.
  2. The filers (the "Filers") are Stonepine Capital Management, LLC (the "General Partner"), Stonepine Capital, L.P. (the "Partnership"), Jon M. Plexico and Timothy P. Lynch. The General Partner is the general partner and investment adviser of investment funds, including the Partnership (collectively, the "Funds"). Mr. Plexico and Mr. Lynch are the General Partner's managers and control persons. These securities are held directly by the Funds for the benefit of their investors and are indirectly beneficially owned by the General Partner and Mr. Plexico and Mr. Lynch as the General Partner's control persons. The General Partner is filing this Form 4 for itself and the other Filers.
  3. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Each Filer disclaims beneficial ownership of these securities except to the extent of that Filer's pecuniary interest therein.
  4. These securities were sold by the Partnership, which held 2,443,843 shares after the transaction on May 3 and 2,271,843 shares after the transaction on May 4.
  5. These securities were sold by the other Funds.
  6. This is a weighted average price. These securities were sold in multiple transactions at prices ranging from $7.69 to $7.838.